SHANGHAI and NEW YORK, December 8, 2020 -- 3D Medicines, Inc., a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated next-generation immuno-oncology drugs, and SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS”), a late-stage clinical biopharmaceutical company focusing on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that they have entered into an Exclusive License Agreement granting rights to 3D Medicines to develop and commercialize SELLAS’ lead clinical candidate, galinpepimut-S (GPS) and next-generation candidate GPS+ at preclinical stage, across all therapeutic and diagnosis uses in the Greater China territory (mainland China, Hong Kong, Macau and Taiwan).
November 16, 2020, 3D Medicines Inc. announced the New Drug Application (NDA) of Envafolimab (KN035), a recombinant humanized PD-L1 single-domain antibody, which has reached the strategic collaboration with Alphamab Biopharmaceuticals Co., Ltd. (9966.HK) and Simcere Pharmaceutical Group Ltd. (2096.HK). The application has been officially submitted to the National Medical Products Administration (NMPA), and the indications are for the treatment of microsatellite instability (MSI-H) in advanced colorectal cancer, gastric cancer, and other mismatch repair defective (dMMR) advanced solid cancers that have failed previous standard treatment.
Shanghai, October 16, 2020 – 3D Medicines announced that a new laboratory building for Translational Medicine Center came into service, and the R&D capabilities continued to grow.
Beijing, China, May 29, 2020 - 3D Medicines, Inc.,a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated next-generation immuno-oncology drugs, today published the latest clinical trial results for Subcutaneous PD-L1 Antibody Envafolimab(KN035)on the 2020 annual meeting of American Society of Clinical Oncology (ASCO), under the title of “Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency”.
Beijing, China, March 30, 2020 – 3D Medicines announced that 3D Medicines (Beijing) Co., Ltd., a wholly-owned subsidiary of 3D Medicines, Inc., has established strategic partnership with Simcere Pharmaceuticals and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Jiangsu Alphamab”)to advance the development and commercialization of Envafolimab (KN035), a checkpoint inhibitor for programmed cell death ligand-1 (PD-L1), for the treatment of cancer indications in mainland China.
January 18, 2020 – 3D Medicines, Inc. (“3D Medicines”)and Alphamab Oncology (stock code: 9966.HK) (“Alphamab”) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PD-L1 antibody KN035 for the treatment of biliary tract cancer (BTC).